Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Celcuity Inc. is $165.00, about 79.2% above its August 12 closing price of $92.08
What drove results
- COMMERCIAL LAUNCH PREPARATIONS - Co said higher SG&A expenses were mainly due to hiring and costs related to the anticipated launch of REVTORPYK
- R&D COST CHANGES - Co said R&D expenses fell due to lower clinical trial and license milestone costs, partly offset by higher employee and manufacturing costs
- CLINICAL AND REGULATORY MILESTONES - Co highlighted FDA approval of REVTORPYK and positive Phase 3 trial results as key recent achievements
Outlook and upcoming milestones
- Company expects to begin shipping REVTORPYK late in the third quarter 2026
- Celcuity plans to submit sNDA for gedatolisib in the third quarter 2026
- Company expects to provide clinical updates on prostate cancer and subcutaneous formulation in Q4 2026
Quarterly results beat expectations
CELC•
